scholarly journals Angiotensin Receptor Blockers in cardiovascular diseases: attention to Irbesartan

2017 ◽  
Vol 0 (9-10(215-6) ◽  
pp. 17-27
Author(s):  
V. G. Lizogub ◽  
E. G. Kupchinskaya ◽  
A. A. Bugaytsev
Author(s):  
Suna Aydin ◽  
Ramazan Fazil Akkoc ◽  
Suleyman Aydin

Nowadays Coronavirus Disease 2019 (Covid-19) is increasing mortality all over the world mercilessly. We are learning almost every day about its new symptoms and that it mutates quickly. This disease has tied us up and made us desperate. The death rate from this disease has increased in patients who had pre-existing medical conditions, especially cardiovascular ones, by eliminating the angiotensin-converting enzyme (ACE)-2 receptor in the lungs. Also, ACE1 and angiotensin receptor blockers (ARB) may stimulate ACE2 expression and worse the prognosis. Intravenous infusions of ACEIs and ARBs in experimental animals increase the number of ACE2 receptors. Therefore, it may be one of the reasons that COVID-19 infects the cells of patients treating hypertension. However, most of the congress of cardiology do not recommend to discontinue these anti-hypertensive drugs. Therefore, this brief report evaluates Covid-19 in the view of cardiovascular diseases taking into account current reports and suggests some possible solutions to keep the virus under control.


Author(s):  
Anuroop Sood ◽  
Jismi Joseph ◽  
Sneha Mathew ◽  
Subramanyam K ◽  
Rajesh Ks ◽  
...  

Objectives: The objective of this study was to assess the prescribing pattern, most common indication, and adverse effects associated with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with cardiovascular diseases, and to identify the risk factors associated with cardiovascular diseases in a tertiary care hospital.Methods: A prospective observational study was carried out for a period of 6 months from October 2016 to March 2017 in both inpatients and outpatients of the cardiology department. Patients received either ACEIs or ARBs were enrolled in the study. The relevant details of the patients were collected from the patient case note and treatment chart and data analyzed.Results: Of 100 patients, 23.0% were female and 77.0% were male. Among them, majority of patients were in the age group of 41–60 years. Diabetes mellitus (39%), smoking (20%), and alcohol (14%) were the common risk factors. The most common indications of ACEIs were found to be ischemic heart diseases (IHDs) (17%) followed by hypertension (HTN)/IHD (12%), and IHD/heart failure (12%). Main indications of ARBs were found in HTN/ IHD (16%). Utilization of ACEIs (70%) was found to be higher when compared with ARBs (30%). Ramipril (69%) and telmisartan (18%) were the most commonly used ACEIs and ARBs, respectively. While analyzing the adverse effects of ACEIs and ARBs, about 5.71% of patients were identified with ramipril induced dry cough.Conclusions: The complications of cardiovascular diseases can be reduced by knowing the incidence of risk factors and alternative therapy can be initiated by assessing the incidence of adverse drug reactions related to ACEIs and ARBs


Sign in / Sign up

Export Citation Format

Share Document